Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Reply.

Pope JE, Rothfield NF, Ramsey-Goldman R, Douglas Smith C, Bernatsky SR, Furie RA, Hudson M, Burgos-Vargas R, Senécal JL, Inanç M, van Vollenhoven RF, Chandran V, Nash PT, Muangchan C.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):1053-4. doi: 10.1002/acr.22777. No abstract available.

2.

Treatment Algorithms in Systemic Lupus Erythematosus.

Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inanç M, Rothfield NF, Nash PT, Furie RA, Senécal JL, Chandran V, Burgos-Vargas R, Ramsey-Goldman R, Pope JE.

Arthritis Care Res (Hoboken). 2015 Sep;67(9):1237-45. doi: 10.1002/acr.22589.

3.

Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients.

Hager WD, Collins I, Tate JP, Azrin M, Foley R, Lakshminarayanan S, Rothfield NF.

Clin Respir J. 2013 Jul;7(3):227-36. doi: 10.1111/j.1752-699X.2012.00310.x. Epub 2012 Aug 10.

PMID:
22789029
4.

Progression of esophageal dysmotility in systemic sclerosis.

Vischio J, Saeed F, Karimeddini M, Mubashir A, Feinn R, Caldito G, Striegel K, Rothfield N.

J Rheumatol. 2012 May;39(5):986-91. doi: 10.3899/jrheum.110923. Epub 2012 Mar 1.

PMID:
22382346
5.

Osteonecrosis in SLE.

Abeles M, Abeles AM, Urman J, Rothfield N.

Rheumatol Int. 2012 Mar;32(3):833. doi: 10.1007/s00296-011-1815-0. Epub 2011 Feb 22. No abstract available.

PMID:
21340569
6.

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2009 Apr;60(4):1102-11. doi: 10.1002/art.24380.

7.

MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.

Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM.

Arthritis Rheum. 2009 Mar;60(3):870-7. doi: 10.1002/art.24351.

8.

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE.

Arthritis Rheum. 2008 Jun;58(6):1810-22. doi: 10.1002/art.23501.

9.

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G; Scleroderma Lung Study Research Group.

Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34. Epub 2007 Aug 23.

10.

Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.

Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group.

Arthritis Rheum. 2007 May;56(5):1676-84.

11.

Outcome measurements in scleroderma: results from a delphi exercise.

Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman MH, Moreland LW, Rothfield NF, Hsu V, Mayes M, McKown KM, Krieg T, Siebold JR.

J Rheumatol. 2007 Mar;34(3):501-9. Epub 2007 Feb 1.

PMID:
17299843
12.

Lupus erythematosus: systemic and cutaneous manifestations.

Rothfield N, Sontheimer RD, Bernstein M.

Clin Dermatol. 2006 Sep-Oct;24(5):348-62. Review.

PMID:
16966017
13.

Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma.

Alkotob ML, Soltani P, Sheatt MA, Katsetos MC, Rothfield N, Hager WD, Foley RJ, Silverman DI.

Chest. 2006 Jul;130(1):176-81.

PMID:
16840399
14.

Cyclophosphamide versus placebo in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group.

N Engl J Med. 2006 Jun 22;354(25):2655-66.

15.

Systemic lupus erythematosus evolving into rheumatoid arthritis.

Rothfield NF, Lim AA.

J Rheumatol. 2006 Jan;33(1):188-90.

PMID:
16395767
16.

Measuring disability: application of the Rasch model to activities of daily living (ADL/IADL).

Sheehan TJ, DeChello LM, Garcia R, Fifield J, Rothfield N, Reisine S.

J Outcome Meas. 2001-2002;5(1):839-63.

PMID:
16320552
17.

Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium.

J Rheumatol. 2005 May;32(5):832-40.

PMID:
15868618
18.

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.

Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group.

Arthritis Rheum. 2005 Feb;52(2):592-600.

19.

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.

Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.

Arthritis Rheum. 2004 Sep;50(9):2858-68.

20.

Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.

Mayes MD, O'Donnell D, Rothfield NF, Csuka ME.

Arthritis Rheum. 2004 Feb;50(2):553-7.

21.

A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories.

Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK, Gordon TP, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wilson M, Byrd MG, Slivka L, Koziol JA.

J Rheumatol. 2003 Nov;30(11):2374-81.

PMID:
14677180
22.

A comparison of self-reports of distress and affective disorder diagnoses in rheumatoid arthritis: a receiver operator characteristic analysis.

McQuillan J, Fifield J, Sheehan TJ, Reisine S, Tennen H, Hesselbrock V, Rothfield N.

Arthritis Rheum. 2003 Jun 15;49(3):368-76. Erratum in: Arthritis Rheum. 2003 Oct 15;49(5):740.

23.

Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis.

Carlson E, Rothfield N.

Arthritis Rheum. 2003 Apr;48(4):1165-6; author reply 1166. No abstract available.

24.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2002 Sep;46(9):2410-20.

25.

A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content.

Tan EM, Smolen JS, McDougal JS, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wiik A, Wilson M, Koziol JA.

J Rheumatol. 2002 Jan;29(1):68-74.

PMID:
11824974
26.

History of affective disorder and the temporal trajectory of fatigue in rheumatoid arthritis.

Fifield J, McQuillan J, Tennen H, Sheehan TJ, Reisine S, Hesselbrock V, Rothfield N.

Ann Behav Med. 2001 Winter;23(1):34-41.

PMID:
11302354
27.

Measuring disability: application of the Rasch model to activities of daily living (ADL/IADL).

Sheehan TJ, DeChello LM, Garcia R, Fifield J, Rothfield N, Reisine S.

J Outcome Meas. 2000-2001;4(3):681-705.

PMID:
11253903
28.

Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.

Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N.

J Rheumatol. 2001 Jan;28(1):102-8.

PMID:
11196509
29.

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME.

Ann Intern Med. 2000 Jun 6;132(11):871-9.

PMID:
10836913
30.

A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity.

Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Rothfield NF, Smeenk R, Takasaki Y, van Venrooij WJ, Wiik A, Wilson M, Koziol JA.

Arthritis Rheum. 1999 Mar;42(3):455-64.

31.

Toward optimal health: the experts respond to arthritis. Interview by Jodi Godfrey Meisler.

Rothfield N, Ettinger W.

J Womens Health. 1998 Sep;7(7):805-9. No abstract available.

PMID:
9785305
32.

Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment.

Pignone A, Scaletti C, Matucci-Cerinic M, Vázquez-Abad D, Meroni PL, Del Papa N, Falcini F, Generini S, Rothfield N, Cagnoni M.

Clin Exp Rheumatol. 1998 Sep-Oct;16(5):527-32.

PMID:
9779298
33.

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.

Arthritis Rheum. 1998 Apr;41(4):670-7.

PMID:
9550476
34.

Range of antinuclear antibodies in "healthy" individuals.

Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA.

Arthritis Rheum. 1997 Sep;40(9):1601-11.

PMID:
9324014
35.

Analysis of IgG subclasses of human antitopoisomerase I autoantibodies suggests chronic B cell stimulation.

Vázquez-Abad D, Monteón V, Senécal JL, Walsh S, Rothfield N.

Clin Immunol Immunopathol. 1997 Jul;84(1):65-72.

PMID:
9191885
36.

A cross-reactive idiotype in scleroderma.

Vázquez-Abad D, Tian L, Zanetti M, Rothfield NF.

Clin Exp Immunol. 1997 Jun;108(3):420-7.

37.

CRI-EM is a human idiotype highly specific for scleroderma.

Vázquez-Abad D, Tian L, Monteón V, Zanetti M, Rothfield NF.

Ann N Y Acad Sci. 1997 Apr 5;815:512-5. No abstract available.

PMID:
9186713
38.

Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting.

Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, Lahita R, Maini RN, Reeves W, Reichlin M, Rothfield N, Takasaki Y, van Venrooij WJ, Tan EM.

Arthritis Rheum. 1997 Mar;40(3):413-8.

PMID:
9082926
39.

Racial aspects of comorbidity in systemic lupus erythematosus.

Walsh SJ, Algert C, Rothfield NF.

Arthritis Care Res. 1996 Dec;9(6):509-16.

PMID:
9136295
40.

Chiasmal herniation as a complication of bromocriptine therapy.

Taxel P, Waitzman DM, Harrington JF Jr, Fagan RH, Rothfield NF, Chen HH, Malchoff CD.

J Neuroophthalmol. 1996 Dec;16(4):252-7.

PMID:
8956160
41.

Localization of histidyl-tRNA synthetase (Jo-1) in human laryngeal epithelial carcinoma cell line (HEp-2 cells).

Vázquez-Abad D, Carson JH, Rothfield N.

Cell Tissue Res. 1996 Dec;286(3):487-91.

PMID:
8929351
42.

Antimalarial drugs in pregnancy--the North American experience.

Parke AL, Rothfield NF.

Lupus. 1996 Jun;5 Suppl 1:S67-9. Review.

PMID:
8803915
43.

Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis.

Vázquez-Abad D, Rothfield NF.

Arthritis Rheum. 1996 Feb;39(2):292-6.

PMID:
8849382
44.

Divergent racial trends in mortality from systemic lupus erythematosus.

Walsh SJ, Algert C, Gregorio DI, Reisine ST, Rothfield NF.

J Rheumatol. 1995 Sep;22(9):1663-8.

PMID:
8523342
46.

Longitudinal study of anticentromere and antitopoisomerase-I isotypes.

Vázquez-Abad D, Russell CA, Cusick SM, Earnshaw WC, Rothfield NF.

Clin Immunol Immunopathol. 1995 Mar;74(3):257-70.

PMID:
7859416
47.

Autoantibodies in systemic sclerosis.

Vázquez-Abad D, Rothfield NF.

Int Rev Immunol. 1995;12(2-4):145-57. Review.

PMID:
7650418
48.

Autoantibodies in scleroderma and tightskin mice.

Bona C, Rothfield N.

Curr Opin Immunol. 1994 Dec;6(6):931-7. Review.

PMID:
7710717
49.

Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen.

Vázquez-Abad D, Wallace S, Senécal JL, Joyal F, Roussin A, Earnshaw WC, Rothfield N.

Arthritis Rheum. 1994 Feb;37(2):248-52.

PMID:
8129780
50.

Analysis of human antitopoisomerase-I idiotypes.

Vazquez-Abad D, Pascual V, Zanetti M, Rothfield NF.

J Clin Invest. 1993 Sep;92(3):1302-13.

Supplemental Content

Loading ...
Support Center